GAITHERSBURG, Md.--(BUSINESS WIRE)--Calibrant Biosystems today announced a research collaboration with the Yale University School of Medicine to identify novel ovarian and breast cancer drug targets from clinical tissue specimens using Calibrant’s Gemini proteomics platform. Calibrant will identify proteins and protein networks involved in ovarian and breast cancer, as well as select novel therapeutic targets found to be central to disease progression.
